Abstract:Background: The carefully orchestrated events that result in a protective immune response are coordinated to a large extent by cytokines produced by T helper 1 (Th1) and T helper 2 (Th2) T-cell subsets, which are two arms of the immune system, Th1 cells preferentially produce interleukin 2 (IL-2), interferon gamma (IFN gamma), and tumor necrosis factor (TNF), resulting in a cellular response that helps to eliminate infected cells, In contrast, Th2 cells produce IL-4, IL-5, IL-6, and IL-10 and stimulate an antibody response that helps to prevent the cells from becoming infected, The clinical progression of several infectious diseases, including human immunodeficiency virus, some types of parasitoses, and tuberculosis, is thought to be associated with the predominance of a Th2-type T-cell response, Recent reports have demonstrated the presence of T cells producing Th2 lymphokines (IL-4, IL-6, and IL-10) in tumor-infiltrating lymphocytes of renal cell carcinoma, Purpose: The purpose of this study was to investigate at the molecular level whether there was any change in the splenic T cells of mice with progressively growing tumors from a Th1 to a Th2 DNA-binding pattern or phenotype, Methods: Splenic T cells from mice bearing renal cell carcinoma or MCA-38 colon carcinoma were tested for cytokine production after in vitro activation, Nuclear extracts of splenic T cells were used for the DNA-binding assay using IFN-gamma core promoter region, the kappa B (kappa B) Site from immunoglobulin gene, and the nuclear factor of activated T-cell (NFAT) site from IL-2 gene, Results: Splenic T cells from mice bearing renal cell carcinoma or MCA-38 colon carcinoma preferentially produced Th2 cytokines (i.e., IL-4) upon activation and showed a marked decrease in Th1 cytokine (particularly IFN gamma) production compared with the production observed in normal splenic T cells, The DNA-binding assay with the IFN-gamma core promoter region confirmed the gradual decline in the nuclear transcription factors associated with the Th1 phenotype during tumor progression in both tumor models, Renal cell carcinoma-bearing mice, successfully treated with flavone-8-acetic acid and recombinant human IL-2, showed a reversion to a Th1-like pattern, In addition, nuclear extracts of T cells from tumor-bearing animals showed a Th2-type kappa B-binding pattern, Moreover, the NFAT complex present in the normal splenic T cells was lost at the later stages of tumor progression; instead, a new complex was present in mice bearing long-term tumors, Conclusion: T cells from tumor-bearing mice lose the Th1 phenotype with progressive tumor growth.

Tumor Cell Responses to IFNγ Affect Tumorigenicity and Response to IL-12 Therapy and Antiangiogenesis

IFN-γ Mediates CD4+ T-cell Loss and Impairs Secondary Antitumor Responses after Successful Initial Immunotherapy

Genome-Wide Analysis of Molecular Changes in IL-12-Induced Control of Mammary Carcinoma Via IFN-γ-Independent Mechanisms

Tumor-Induced Suppression of Interferon-Gamma Production and Enhancement of Interleukin-10 Production by Natural Killer (nk) Cells: Paralleled to Cd4(+) T Cells

Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy

Interferon Gamma Inhibits CXCL8-Induced Proliferation and Migration of Pancreatic Cancer BxPC-3 Cell Line Via a RhoGDI2/Rac1/NF-κB Signaling Pathway.

Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma

Interferon-gamma signaling promotes melanoma progression and metastasis

Roles of IFN-γ in tumor progression and regression: a review

IFNγ‐responsiveness of Endothelial Cells Leads to Efficient Angiostasis in Tumours Involving Down‐regulation of Dll4

Type I Interferon Suppresses Tumor Growth Through Activating the STAT3-granzyme B Pathway in Tumor-Infiltrating Cytotoxic T Lymphocytes

IL-12 Enhances Immune Response by Modulation of Myeloid Derived Suppressor Cells in Tumor Microenvironment

Reciprocal effects of Th1 and Treg cell inducing pathogen-associated immunomodulatory molecules on anti-tumor immunity

Interferon-γ: teammate or opponent in the tumour microenvironment?

Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non–Small Cell Lung Cancer

Therapeutic Activity of High-Dose Intratumoral IFN-β Requires Direct Effect on the Tumor Vasculature.

Role of IFN Regulatory Factor-1 and IL-12 in Immunological Resistance to Pathogenesis of N-Methyl-N- Nitrosourea-Induced T Lymphoma

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.

Anti-proliferative effect of IFN-gamma in immune regulation. II. IFN-gamma inhibits the proliferation of murine bone marrow cells stimulated with IL-3, IL-4, or granulocyte-macrophage colony-stimulating factor.

IFN-γ Promotes Graft-Versus-leukemia Effects Without Directly Interacting with Leukemia Cells in Mice after Allogeneic Hematopoietic Cell Transplantation.